Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
4.800
+0.580 (13.74%)
At close: Feb 6, 2026, 4:00 PM EST
4.750
-0.050 (-1.04%)
After-hours: Feb 6, 2026, 7:41 PM EST
Minerva Neurosciences Employees
Minerva Neurosciences had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,753,445
Market Cap
207.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | 0 | - |
| Dec 31, 2021 | 9 | -2 | -18.18% |
| Dec 31, 2020 | 11 | -2 | -15.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Voyager Therapeutics | 172 |
| Tonix Pharmaceuticals Holding | 81 |
| SAB Biotherapeutics | 63 |
| Camp4 Therapeutics | 55 |
| Surrozen | 41 |
| Sol-Gel Technologies | 34 |
| Ovid Therapeutics | 23 |
| Galectin Therapeutics | 15 |
NERV News
- 4 days ago - Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript - Seeking Alpha
- 13 days ago - Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - GlobeNewsWire
- 2 months ago - Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors - GlobeNewsWire
- 3 months ago - Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 3 months ago - Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved - GlobeNewsWire
- 6 months ago - Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results - GlobeNewsWire
- 9 months ago - Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates - GlobeNewsWire